Lung cancer is a lethal malignancy that kills approximately 158,000 individuals in the United States yearly, accounting for more deaths than the next four most lethal types of cancer combined. 1 Only 17% of all patients who are not screened survive for 5 years or more, likely because of the fact that 56% of unscreened individuals with lung cancer have metastatic disease at presentation. 2 In 2011, the National Lung Screening Trial (NLST) demonstrated at least a 20% reduction of lung cancer death with the use of a low-dose computed tomography (LDCT) scan in select high-risk populations. 3 There has been consistent and widespread support for lung cancer screening (LCS) by multispecialty professional societies, the U.S. Preventive Services Task Force Services, 4 and the Centers for Medicare and Medicaid Services (CMS). 5 Both the U.S. Preventive Services Task Force Services and CMS outline specific recommendations for coverage of LCS for high-risk populations, including the need for a multidisciplinary approach. To ensure a collaborative and comprehensive patient care environment, thoracic surgeons should be at the forefront in the design and structuring of LCS programs. This includes designing patient care algorithms for diagnosis, follow-up, staging, biopsy, resection and treatment. Whereas the Society of Thoracic Surgeons outlined the role of thoracic surgeons in LCS, 6 we explore why thoracic surgeons should have active participation in the design of LCS practice to minimize risk and maximize benefits to the screened individual.
Thoracic Surgeons' Perspective of Lung Nodules
Thoracic surgeons provide an additional and necessary perspective in the interpretation of LDCT and lung nodules. Chronic obstructive pulmonary disease, infectious nodules, other benign lung diseases, and previous lung surgery can confound the interpretation of LDCT scans. Additional interpretations of scans from different clinical perspectives are critical, as radiographic interpretation of lung nodules is an area of great variability. Armato et al. 7 demonstrated that only two-thirds of the nodules identified by either radiologist A or radiologist B were also identified by the other. A single radiologic interpretation of a scan may not suffice, especially when making recommendations on follow-up or diagnostic procedures. Thoracic surgeons can formulate a plan based not only on the LDCT scan but also on the patient's clinical context. A major concern with computed tomography (CT) screening are the large numbers of indeterminate pulmonary nodules and false-positive results. The NLST reported that 39.1% of people experienced at least one false-positive result in 3 years of LDCT scanning.
3 Of all patients with positive screens, 81.1% required only additional imaging to resolve a concern for lung cancer.
3 NLST participants rarely received intervention (percutaneous biopsy rate 2.2%, bronchoscopy rate 4.3%, and surgery rate 4.2%).
3 With implementation of LCS outside of a clinical trial, physicians may opt for an immediate, definitive tissue diagnosis over radiographic follow-up of positive results.
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When asked to perform a biopsy on nodules found on LCS, interventional radiologists, interventional pulmonologists, and surgeons must exercise judicious use of biopsy procedures. The judgment, experience, and input of surgeons and interventionalists may help guide referring physicians and patients to follow up positive results with imaging when indicated. Surgeons will also provide a perspective of efficient biopsy strategy. A nodule suggestive of malignancy may warrant surgical resection without biopsy; alternatively, a biopsy may be performed on lymph nodes suggestive of malignancy to obtain both a tissue diagnosis and staging information with a single procedure. Follow-up of nodules should be a patient-centered process with multidisciplinary support. A tangible downside of LCS is complications from interventions. Thoracic surgeons can provide consultation regarding perioperative risk before bronchoscopy, needle biopsy, endobronchial ultrasound, and surgery. By appropriately managing smoking, diabetes, anticoagulation, heart disease, and other comorbidities, surgeons may decrease perioperative or periprocedural risks. Involvement of thoracic surgeons is critical to avoiding unnecessary procedures and minimizing complications from necessary procedures.
Thoracic Surgeons and SDM
CMS requires that a shared decision-making (SDM) visit precede each LDCT scan. Though persuasion is germane to the importance of longitudinal care of screened patients, the intent of SDM before LDCT is to discuss screening benefits and harm and lead patients to a decision that is best for them. Providers have cited time pressures and limited reimbursement as serious constraints to SDM. 8 Contributing barriers to SDM may also include a lack of formal training or unfamiliarity with the practice.
Fortunately, SDM is a concept that is engrained in surgical education. Surgeons guide patients through decision processes, including weighing of the potential benefits and harm of surgery, as well as alternative treatment options. Surgeons routinely apply current evidence to an individual patient's care, highlighting the issues that are most relevant to that patient. Ideally, a collaborative effort between thoracic surgeons, primary care physicians, and specialists will shape the SDM experience for patients undergoing LCS.
Thoracic Surgeons and Smoking Cessation
The screening setting presents an opportunity to address active smokers and former smokers with the potential for relapse. Smoking cessation can extend mean life span as much as 19 to 20 years. 9 As fewer than 2% to 4% of screened patients will have lung cancer and more than 50% are active smokers, 3 smoking cessation may have a greater impact on morbidity and mortality than the actual LDCT and early detection of cancer. Surgeons have a relatively successful experience in smoking cessation compared with those in nonsurgical specialties. 10 Thoracic surgeons frequently ready patients for diagnosis and treatment of lung cancer, and thus, they use aggressive time lines and methods to quitting smoking, including oral smoking cessation medications, nicotine replacement, and counseling. Whether surgeons' success with smoking cessation is a result of the aggressive approach or the urgency to prepare for surgery is unknown. Regardless, an aggressive approach to tobacco cessation should be implemented in the setting of LCS.
Smoking cessation in the setting of LCS presents unique challenges. Smokers commonly face the barriers of nicotine dependence, fatalistic attitudes about cessation benefits, psychological distress, presence of smokers in their social network, and lack of support. However, smokers undergoing LCS are asymptomatic and have no urgency to quit. In one study of smokers, the abstinence rate was actually lower in those undergoing LSC than in the controls. 11 These results raised the concern that people receiving negative screening results may feel validated to continue smoking. However, other studies have demonstrated that a negative screening result does not decrease smoking abstinence. 12, 13 Surgeons can contribute experience and expertise to the multidisciplinary effort of smoking cessation. Smoking interventions by more than one type of health professional have the potential to substantially increase quitting and readiness to quit.
14 If patients receive smoking cessation support from each health care professional involved with LCS, perhaps smoking abstinence can increase. Further study of smoking behavior and the impact of interventions will be needed.
Thoracic Surgery Practice in the Era of LCS
With increasing implementation of LCS and enhanced resolution of CT scanning devices, pulmonary lesions will be detected with higher frequency. Both general surgeons and thoracic surgeons will be asked to participate in the selection of patients to receive intervention or an operation. Furthermore, the International Early Lung Cancer Action Program data demonstrate an increase in the use of video-assisted thoracoscopic surgery from 10% to 34%. 15 The success of the NLST was partly due to the extremely low operative mortality rate of less than 0.5% in those patients with a positive screening result who underwent surgery. The authors of the study have pointed out that the trial was conducted at hospital centers that had pioneered minimally invasive techniques and enjoyed some of the lowest operative mortalities reported.
3 As a consequence of this observation, the Society of Thoracic Surgeons Task Force strongly recommends that CT screening programs have ready access to minimally invasive diagnostic and therapeutic procedures. 6 Thoracic Surgery and Future of LCS Thoracic surgery is integral to the continuing evolution of biomarkers in lung cancer. The NLST has created a surge of interest in biomarkers to diagnose early lung cancer or distinguish benign from malignant nodules that can also serve as a noninvasive and cost-effective way to identify those at risk who should undergo screening or more aggressive diagnostic strategies. A coordinated effort between research teams and clinical teams including thoracic surgeons may establish guidelines for biomarker acquisition and implementation of results, which may in turn help reduce the number of unnecessary invasive procedures. 16 
Conclusion
Thoracic surgeons have a unique perspective that can enrich and enhance the value of LCS and are the ideal providers to minimize risk by using evidence-based and rational decision making as to whether and how to intervene and optimize care should intervention be required, thus greatly contributing to the success and safety of a LCS program. However, participation in LCS is a skill for which thoracic surgeons must invest time to acquire and manage. Whether to devote one's efforts to LCS will ultimately be each thoracic surgeon's choice. Similarly, it will be the choice of professional societies and editors within the field of thoracic surgery to support education and research on LCS.
